Across TCGA pan-cancer cohorts, AGAP9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AGAP9 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher AGAP9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGAP9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and SARC are the cancer types where AGAP9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.048	0.667	<.001	18	view →
UCEC	DFS	Median	All	1.000	0.626	.010	14	view →
SARC	DFS	Median	All	0.081	0.632	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.257	0.731	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AGAP9 tumor-vs-normal RNA expression · all AGAP9 data types